New transparency requirements, loss of safe harbor for PBMs and drugmakers in proposed rule
The Trump administration is calling for pharmacy benefit managers to disclose to health plans the fees that they get from drug companies for administrative services as part of a bid to boost transparency among PBMs…Read More.
Trump, claiming progress in lowering drug prices, tells Congress ‘we must do more’
In his State of the Union address Tuesday, President Trump touted his administration’s work to reduce the price of prescription drugs and called on Congress to take further action…Read More.
Focus on Drug Prices Likely in State of the Union, Experts Say
It’s time for one of Washington’s favorite parlor games: guessing what the president will say in his State of the Union speech…Read More.
Trump’s New Pharmacy Benefit Manager Rebate Rule Will Reshape Prescription Drug Prices
On Thursday, U.S. Health and Human Services Secretary Alex Azar released a long-anticipated rule that could transform the prices that people pay for prescription drugs, and the broader pharmaceutical market…Read More.
National LTC Pharmacy Group: Senate, House Drug Pricing Hearings Kick-Off Vital 2019 Discussion on Transparency, Accountability, Reform
SCPC Urges Sweeping Congressional Focus on PDP/PBM Abuses, Culpability in Market Manipulation…Read More.
National LTC Pharmacy Group to CMS: Abolish DIR Fees – “A Windfall Profit” for Prescription Drug Plans (PDPs) and Pharmacy Benefit Managers (PBMs)
Citing Unique Nature of LTC Pharmacies and Elderly Patients They Serve, Senior Care Pharmacy Coalition (SCPC) Viewpoint on DIR Fees Differs from Other Pharmacy Sector Groups…Read More.
Comment Letter: CMS Proposed Rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses
RE: CMS Proposed Rule: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS 4180-P, RIN 0938-AT92, 83 Fed. Reg. 62152…Read More.
Pharmacy benefit managers marked up generic drugs for NY Medicaid, but where’d the money go?
Amid intensifying scrutiny of medicine costs, an analysis of the New York Medicaid and pharmacy data suggests that pharmacy benefit managers are increasingly marking up generic drugs, raising questions about the extent to which the profits are passed back to the state health care program…Read More.
Walmart blasts CVS drug middleman role, ends business relationship
The Columbus Dispatch
Walmart declared war on CVS when it blasted the pharmacy giant Tuesday and announced it will stop doing most business with CVS’s pharmacy benefit manager…Read More.
Grassley: Finance Committee Will Discuss PBM Transparency Bill
Inside Health Policy
Senate Finance Committee Chairman Sen. Chuck Grassley (R-IA) will discuss a bill on pharmacy benefit manager transparency this session with his committee, a spokesman for the senator told Inside Health Policy…Read More.